GoHealth Beheer
Beheer criteriumcontroles 1/4
De CEO GoHealth is Vijay Kotte, benoemd in Jun2022, heeft een ambtstermijn van 3.92 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 13.76M, bestaande uit 7% salaris en 93% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 5.69% van de aandelen van het bedrijf, ter waarde $ 1.09M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.1 jaar en 0.8 jaar.
Belangrijke informatie
Vijay Kotte
Algemeen directeur
US$13.8m
Totale compensatie
| Percentage CEO-salaris | 7.05% |
| Dienstverband CEO | 3.9yrs |
| Eigendom CEO | 5.7% |
| Management gemiddelde ambtstermijn | 3.1yrs |
| Gemiddelde ambtstermijn bestuur | less than a year |
Recente managementupdates
Recent updates
Narratiefupdate • Apr 30
GOCO: Lower P E And Improved Revenue Outlook Will Support Returns
Analysts have cut their 12 month price target for GoHealth by about $3, reflecting a reset in fair value assumptions along with updated views on revenue growth, margins and future P/E, following a recent downgrade highlighted in Street research. Analyst Commentary Bearish analysts are framing the latest downgrade as part of a broader reset in expectations for GoHealth, with the lower 12 month price target seen as a response to questions about how quickly the business can translate its model into consistent, scalable earnings.
Narratiefupdate • Apr 14
GOCO: Lower Earnings Multiple Will Support Upside Despite Nasdaq Compliance Risk
Analysts cut their GoHealth price target from $7.70 to $4.70 as they factor in updated assumptions for revenue growth and margins, and incorporate the recent downgrade at Freedom Broker into their outlook. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$4.70 target as a cleaner entry point that better reflects current expectations for revenue growth and margins, which they see as more achievable under updated assumptions.Narratiefupdate • Mar 31
GOCO: Discount Rate Tweaks Will Support Upside Despite Nasdaq Compliance Risk
Analysts have nudged up their price target on GoHealth to $7.70, citing a slightly lower discount rate and modest tweaks to long term revenue growth, profit margin, and future P/E assumptions as key drivers of the change. What's in the News On March 18, 2026, GoHealth received a notice from Nasdaq that it is not in compliance with the minimum US$35 million market value of listed securities requirement under Listing Rule 5550(b)(2) (Nasdaq filing).Narratiefupdate • Mar 17
GOCO: Stable Assumptions And Low Future P E Will Support Returns
Analysts have kept their GoHealth price target unchanged at $4.50. They point to only slight tweaks in revenue growth, profit margin and forward P/E assumptions that do not materially alter their overall view of the stock.Narratiefupdate • Mar 03
GOCO: Stronger Margins And Lower P E Will Support Future Cash Flow
Analysts have trimmed their price target on GoHealth to reflect slightly weaker revenue expectations, a modestly stronger profit margin, and a marginally lower forward P/E. This results in a small downward adjustment in their $ price outlook for the stock.Narratiefupdate • Feb 17
GOCO: Carrier Relationship Reset Will Support Future Cash Flow Recovery
Analysts have sharply reduced GoHealth's target, with one firm lowering its price target to $5 from $12 after Q3 results came in below expectations because of topline weakness tied to a suspended relationship with a large carrier. Analyst Commentary Bearish analysts are recalibrating their expectations after Q3 results came in well below what they were looking for, and the cut in the price target to $5 from $12 signals a more cautious stance on the stock.Narratiefupdate • Feb 03
GOCO: Cash Burn Discipline And Carrier Reset Could Support Future Upside
Analysts have cut their price targets on GoHealth, including a reduction to US$5 from US$12. They cited weaker than expected Q3 results tied to topline softness from a suspended carrier relationship, a pullback in new enrollment growth, and ongoing concerns about market headwinds and cash flow sustainability.Narratiefupdate • Jan 20
GOCO: Cash Discipline And Carrier Reset Will Support Future Cash Flow
Analysts have sharply reduced their GoHealth price targets, with one moving from US$12 to US$5. This reflects weaker Q3 results tied to a suspended carrier relationship, as well as concerns about ongoing market headwinds and cash flow visibility.Narratiefupdate • Jan 06
GOCO: Focus On Cash Burn Discipline And Carrier Reset Supporting Future Stability
Narrative Update on GoHealth Analysts have cut their 12 month price target for GoHealth to US$5.00 from US$12.00, reflecting weaker Q3 results tied to a suspended relationship with a large carrier, softer revenue and Medicare submissions, a pullback in new enrollment growth, and concerns around ongoing market headwinds and uncertainty about achieving sustainable positive cash flow. Analyst Commentary Recent research updates on GoHealth reflect a cautious reset of expectations following Q3 results that came in below prior estimates, with price targets and ratings adjusted to reflect execution risks and a more uncertain growth outlook.Narratiefupdate • Dec 15
GOCO: Cash Flow Improvements Will Outweigh Carrier Loss And Enrollment Pullback
Analysts have sharply reduced their price target on GoHealth from approximately $12.00 to about $5.00 per share. This reflects weaker than expected Q3 results, revenue headwinds from a suspended carrier relationship, and persistent concerns about the company's ability to deliver sustainable growth and cash flow in a challenging market.Narratiefupdate • Dec 01
GOCO: Focus On Profitability And Cash Burn Reduction Will Drive Future Stability
Analysts have sharply reduced GoHealth's fair value estimate from $14 to $7.70 per share. They cite ongoing market headwinds, weaker-than-expected Q3 results, and challenges in revenue growth as key reasons for the downward revision.Narratiefupdate • Nov 17
GOCO: Recent Credit Move Will Boost Flexibility Ahead of Enrollment Period
Analysts have revised GoHealth's fair value estimate downward from $17.20 to $14.00. This change is due to updated model assumptions and increased caution surrounding revenue growth following recent company results and financial transactions.Narratiefupdate • Aug 25
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth. What's in the News GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.Narratiefupdate • Aug 10
Financial Flexibility And M&A Will Unlock Medicare And Senior Health Potential
Despite higher revenue growth forecasts, GoHealth’s future P/E multiple has dropped sharply, indicating reduced investor confidence in earnings quality or sustainability, leading to a lower consensus price target of $19.60. What's in the News GoHealth has formed a Transformation Committee to evaluate acquisitions, financial structure options, securitizations, and other strategic opportunities for value creation.
Nieuw narratief • Mar 31
Medicare Engagement And Efficiency Will Drive Future Savings
GoHealth's shift to Medicare engagement enhances consumer relations and boosts operational efficiency, lowering costs and improving margins.Seeking Alpha • May 28
GoHealth: Turning The Corner On Operating Cash Flow
Summary GoHealth's shares have continued to drop despite positive developments, presenting an opportunity for investors to build a position over time. The company has shown positive operating cash flow for five consecutive quarters, reflecting a shift towards profitability and cost containment. Although GOCO previously needed to rely on debt funding, it is now deleveraging, and its focus on operating cash flow is a positive sign for investors. Read the full article on Seeking AlphaAnalyseartikel • May 10
GoHealth, Inc. (NASDAQ:GOCO) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders will be ecstatic, with their stake up 44% over the past week following GoHealth, Inc. 's ( NASDAQ:GOCO...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$294m |
| Dec 31 2025 | US$14m | US$969k | -US$261m |
| Sep 30 2025 | n/a | n/a | -US$203m |
| Jun 30 2025 | n/a | n/a | -US$30m |
| Mar 31 2025 | n/a | n/a | -US$2m |
| Dec 31 2024 | US$6m | US$900k | -US$7m |
| Sep 30 2024 | n/a | n/a | -US$33m |
| Jun 30 2024 | n/a | n/a | -US$64m |
| Mar 31 2024 | n/a | n/a | -US$67m |
| Dec 31 2023 | US$5m | US$900k | -US$67m |
| Sep 30 2023 | n/a | n/a | -US$127m |
| Jun 30 2023 | n/a | n/a | -US$132m |
| Mar 31 2023 | n/a | n/a | -US$146m |
| Dec 31 2022 | US$10m | US$485k | -US$150m |
Compensatie versus markt: De totale vergoeding ($USD 13.76M ) Vijay } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 627.03K ).
Compensatie versus inkomsten: De vergoeding van Vijay is gestegen terwijl het bedrijf verliesgevend is.
CEO
Vijay Kotte (47 yo)
3.9yrs
Tenure
US$13,757,255
Compensatie
Mr. Vijay Kumar Kotte serves as Chief Executive Officer & Director of GoHealth, Inc. from June 06, 2022. He served as Executive Vice President, Strategy & Corporate Development and Chief Solutions Officer...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.042% $ 8.0k | |
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.11% $ 21.6k | |
| CEO & Director | 3.9yrs | US$13.76m | 5.69% $ 1.1m | |
| Chief Financial Officer | 1.6yrs | US$2.06m | 0.42% $ 81.2k | |
| Chief Operating Officer | 2.8yrs | US$2.19m | 1.25% $ 239.5k | |
| Chief Technology Officer | 1.5yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Legal Officer & Corporate Secretary | 2.3yrs | geen gegevens | 0.14% $ 27.3k | |
| Chief Marketing Officer | 3.3yrs | geen gegevens | geen gegevens | |
| Chief People Officer | 3.3yrs | geen gegevens | geen gegevens | |
| Chief Distribution Officer | 1.3yrs | geen gegevens | geen gegevens |
3.1yrs
Gemiddelde duur
47yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van GOCO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.042% $ 8.0k | |
| Co-Founder & Non-Executive Co-Chairman | 6.3yrs | US$150.00k | 0.11% $ 21.6k | |
| CEO & Director | 3.9yrs | US$13.76m | 5.69% $ 1.1m | |
| Independent Director | 4yrs | US$150.00k | 0.58% $ 110.6k | |
| Director | less than a year | US$135.48k | geen gegevens | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Director | less than a year | US$262.74k | geen gegevens | |
| Director | less than a year | US$262.74k | geen gegevens | |
| Director | less than a year | US$262.74k | geen gegevens |
0.8yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van GOCO wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/24 21:25 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
GoHealth, Inc. wordt gevolgd door 16 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Steven Valiquette | Barclays |
| Steven Valiquette | Barclays |
| Michael Cherny | BofA Global Research |